drugset / Trial / NCT05375084
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Phase 1
Terminated
21 enrolled
Navire Pharma Inc., a BridgeBio company
Bristol-Myers Squibb · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1 study of BBP-398, a SHP2 inhibitor, in combination with nivolumab, a PD-1 antibody, in patients with NSCLC with a KRAS mutation. The study involves 2 parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion.
Timeline
- Start
- 2022-10-20
- Primary completion
- 2024-04-12
- Completion
- 2024-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BBP-398 | Small molecule | — | Oral |
| Background | Nivolumab | Monoclonal antibody | — | Intravenous |